Mineralys Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Mineralys Therapeutics has a total shareholder equity of $241.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $251.6M and $10.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$236.57m |
| Equity | US$241.15m |
| Total liabilities | US$10.48m |
| Total assets | US$251.64m |
Recent financial health updates
We're Hopeful That Mineralys Therapeutics (NASDAQ:MLYS) Will Use Its Cash Wisely
Nov 12
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Jul 03Recent updates
Financial Position Analysis
Short Term Liabilities: MLYS's short term assets ($249.1M) exceed its short term liabilities ($10.5M).
Long Term Liabilities: MLYS has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MLYS is debt free.
Reducing Debt: MLYS had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MLYS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MLYS has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 64.1% each year.